The United States experience with oral controlled-release morphine (MS contin tablets).parts i and ii. review of nine dose titration studies and clinical pharmacology of 15-mg, 30-mg, 60-mg, and 100-mg tablet strengths in normal subjects

Cancer ◽  
1989 ◽  
Vol 63 (11) ◽  
pp. 2348-2354 ◽  
Author(s):  
Robert F. Kaiko ◽  
Robert P. Grandy ◽  
Benjamin Oshlack ◽  
Joseph Pav ◽  
Joseph Horodniak ◽  
...  
Keyword(s):  
United States ◽  
Clinical Pharmacology ◽  
Controlled Release ◽  
Normal Subjects ◽  
The United States ◽  
Dose Titration ◽  
States Experience

Hand transplantation in the United States: Experience with 3 patients

Surgery ◽  
2008 ◽  
Vol 144 (4) ◽  
pp. 638-644 ◽  
Author(s):  
Kadiyala V. Ravindra ◽  
Joseph F. Buell ◽  
Christina L. Kaufman ◽  
Brenda Blair ◽  
Michael Marvin ◽  
...  
Keyword(s):  
United States ◽  
The United States ◽  
Hand Transplantation ◽  
States Experience

Potassium binders

ESC CardioMed ◽  
2018 ◽  
pp. 218-221
Author(s):  
Keld P. Kjeldsen ◽  
Juan Tamargo ◽  
Thomas A. Schmidt
Keyword(s):  
United States ◽  
Clinical Pharmacology ◽  
Gastrointestinal Tract ◽  
The United States ◽  
European Medicines Agency ◽  
Sodium Polystyrene Sulfonate ◽  
United States Food ◽  
States Food ◽  
Potassium Binders ◽  
Sodium Zirconium Cyclosilicate

Potassium binders are used for the treatment of and prophylaxis against hyperkalaemia. Already in 1958, the United States Food and Drug Administration (FDA) approved sodium polystyrene sulfonate, a potassium binder exchanging sodium for potassium in the gastrointestinal tract. In 2015, the FDA approved a new potassium binder, patiromer sorbitex calcium (Veltassa®), exchanging calcium for potassium, and in 2017, it was approved by the European Medicines Agency (EMA). Furthermore, in 2018, the FDA and the EMA approved another new potassium binder, sodium zirconium cyclosilicate (Lokelma®), exchanging sodium for potassium. The clinical pharmacology aspects of potassium binders are reviewed in this chapter.

Potassium binders

ESC CardioMed ◽  
2018 ◽  
pp. 218-221
Author(s):  
Keld P. Kjeldsen ◽  
Juan Tamargo ◽  
Thomas A. Schmidt
Keyword(s):  
United States ◽  
Clinical Pharmacology ◽  
Gastrointestinal Tract ◽  
The United States ◽  
European Medicines Agency ◽  
Sodium Polystyrene Sulfonate ◽  
United States Food ◽  
States Food ◽  
Potassium Binders ◽  
Sodium Zirconium Cyclosilicate

Potassium binders are used for the treatment of and prophylaxis against hyperkalaemia. Already in 1958, the United States Food and Drug Administration (FDA) approved sodium polystyrene sulfonate, a potassium binder exchanging sodium for potassium in the gastrointestinal tract. In 2015, the FDA approved a new potassium binder, patiromer sorbitex calcium (Veltassa®), exchanging calcium for potassium, and in 2017, it was approved by the European Medicines Agency (EMA). Furthermore, in January 2018 approval by the FDA of another new potassium binder, sodium zirconium cyclosilicate (ZS-9®), exchanging sodium for potassium, is pending. The clinical pharmacology aspects of potassium binders are reviewed in this chapter.

Attempts to control health care costs: The United States experience

1979 ◽  
Vol 13 (5) ◽  
pp. 529-540
Author(s):  
John F. Newman ◽  
William B. Elliott ◽  
James O. Gibbs ◽  
Helen C. Gift
Keyword(s):  
United States ◽  
Health Care ◽  
Health Care Costs ◽  
The United States ◽  
States Experience ◽  
Care Costs
Sign in / Sign up

Export Citation Format

Share Document